CIPLA VALGANCICLOVIR valganciclovir (as hydrochloride) 450 mg tablet bottle

Land: Australien

Sprog: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv bestanddel:

valganciclovir hydrochloride, Quantity: 496.3 mg (Equivalent: valganciclovir, Qty 450 mg)

Tilgængelig fra:

Cipla Australia Pty Ltd

INN (International Name):

Valganciclovir hydrochloride

Lægemiddelform:

Tablet, film coated

Sammensætning:

Excipient Ingredients: povidone; stearic acid; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000; iron oxide red

Indgivelsesvej:

Oral

Enheder i pakken:

60 tablets

Recept type:

(S4) Prescription Only Medicine

Terapeutiske indikationer:

CIPLA VALGANCICLOVIR is indicated for the treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).,CIPLA VALGANCICLOVIR is indicated for the prophylaxis of CMV disease in adult and paediatric solid organ transplantation (SOT) patients who are at risk.

Produkt oversigt:

Visual Identification: Pink coloured, capsule shaped, biconvex film coated tablet plain on both sides; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Autorisation status:

Licence status A

Autorisation dato:

2016-09-02